NIOX Group (LON:NIOX) Insider Sarah Duncan Buys 34,127 Shares

NIOX Group Plc (LON:NIOX – Get Free Report) insider Sarah Duncan bought 34,127 shares of the company’s stock in a transaction on Friday, May 29th. The shares were acquired at an average price of GBX 59 per share, with a total value of £20,134.93.

Sarah Duncan also recently made the following trade(s):

Get NIOX Group alerts:

• On Thursday, May 28th, Sarah Duncan bought 34,139 shares of NIOX Group stock. The shares were acquired at an average price of GBX 58 per share, with a total value of £19,800.62.
• On Thursday, May 28th, Sarah Duncan sold 34,219 shares of NIOX Group stock. The shares were sold at an average price of GBX 58, for a total transaction of £19,847.02.
• On Friday, May 29th, Sarah Duncan sold 33,916 shares of NIOX Group stock. The shares were sold at an average price of GBX 59, for a total transaction of £20,010.44.
• On Thursday, April 16th, Sarah Duncan sold 164,612 shares of NIOX Group stock. The shares were sold at an average price of GBX 56, for a total transaction of £92,182.72.

NIOX Group Price Performance

LON:NIOX traded up GBX 0.14 during mid-day trading on Friday, hitting GBX 58.54. 268,082 shares of the company’s stock traded hands, compared to its average volume of 836,268. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.94 and a current ratio of 3.81. The firm’s 50 day simple moving average is GBX 60.09 and its 200 day simple moving average is GBX 64.66. NIOX Group Plc has a 1 year low of GBX 53.84 and a 1 year high of GBX 77.60. The company has a market cap of £246.11 million, a PE ratio of 35.69 and a beta of 0.92.

NIOX Group (LON:NIOX – Get Free Report) last posted its earnings results on Tuesday, March 24th. The company reported GBX 4.03 earnings per share for the quarter. NIOX Group had a net margin of 14.37% and a return on equity of 10.14%. Sell-side analysts expect that NIOX Group Plc will post 1.1658256 EPS for the current year.

About NIOX Group

(Get Free Report)

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.

Further Reading

• Five stocks we like better than NIOX Group
• Salesforce Stock Finds Support as AI Momentum Builds
• Dollar Tree Keeps Winning After Family Dollar Divorce
• Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
• Palomar’s High-Risk Insurance Strategy Is Paying Off Big

Receive News & Ratings for NIOX Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NIOX Group and related companies with MarketBeat.com's FREE daily email newsletter.